Sort
261,768 grants matching “gene therapy”
Multi-Site Validation of Biomarkers and Core Clinical Outcome Measures for Clinical Trials Readiness in CDKL5 Deficiency Disorder
$1,069,127Timothy A Benke · University Of Colorado Denver · U01 · FY2021 · NS
Defining New Human Immunodeficiency and Immunodysregulation Disorders
$1,069,092Helen Su · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
A STINGing vaccine for TB
$1,068,965William Ramses Bishai · Johns Hopkins University · R01 · FY2024 · AI
Genetics of Alzheimer's Disease in Israeli Arabs
$1,068,845Robert Paul Friedland · Case Western Reserve University · R01 · FY2006 · AG
Novel Broad-Spectrum Point-of-Care Coagulometer
$1,068,783Sasha H Bakhru · Perosphere Technologies Inc. · R44 · FY2023 · HL
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment
$1,068,699Suzanne Craft · Wake Forest University Health Sciences · R01 · FY2020 · AG
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment
$1,068,699Suzanne Craft · Wake Forest University Health Sciences · R01 · FY2021 · AG
Asthma Clinical Research Network Center at UCSF
$1,068,624University Of California San Francisco · U10 · FY2003 · HL
Assessment, Therapy and Prevention Of Autoimmune Disease
$1,068,577Frederick Miller · National Institute Of Environmental Health Sciences · ZIA · FY2020 · ES
Mechanisms of Virus Entry into Cells and Antiviral Barriers Limiting Entry
$1,068,562Alex Compton · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Molecular Mechanism of TNF Signaling and Apoptosis
$1,068,246Zheng-Gang Liu · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA
Super-persistent cells and the paradox of untreatable infections
$1,068,216Kim Lewis · Northeastern University · R01 · FY2012 · AI
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding
$1,068,186Jurgen Bernd Bulitta · University Of Florida · R01 · FY2022 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR HIV/AIDS
$1,068,182Miriam Hospital · U01 · FY2002 · AI
Gene Therapy for Urea Cycle Disorders
$1,068,145James M Wilson · University Of Pennsylvania · P01 · FY2013 · HD
Development of mGluR5 Antagonists to Treat Fragile X Syndrome and Autism
$1,068,100Randall L Carpenter · Seaside Therapeutics, Llc · U01 · FY2009 · MH
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
$1,068,000Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2025 · CA
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
$1,068,000Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2021 · CA
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
$1,068,000Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2021 · CA
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
$1,068,000Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2019 · CA
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
$1,068,000Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2020 · CA
Identifying Multilevel Drivers of Differences in Ovarian Cancer Treatment and Survival: An Integrative Approach
$1,067,936Jennifer A. Doherty · Utah State Higher Education System--University Of Utah · R01 · FY2025 · CA
Transplant Models
$1,067,628Ronald Gress · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Immune Reconstitution
$1,067,628Ronald Gress · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)
$1,067,511Trever G Bivona · University Of California, San Francisco · U54 · FY2023 · CA